Page 39 - Exact Sciences News Today

EXAS earnings call for the period ending June 30, 2023.

The biomedical giant best known for its Cologuard test reported a second-quarter loss of $81 million, or 45 cents per share, on revenue of $622.1 million.

Victory Capital Management Inc. lifted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 537.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 126,755 shares of the medical research company’s stock after acquiring an additional 106,872 shares during the period. […]

Exact Sciences Corp (NASDAQ: EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the 

Exact Sciences (NASDAQ:EXAS – Get Free Report) released its earnings results on Tuesday. The medical research company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05, Briefing.com reports. The company had revenue of $622.10 million during the quarter, compared to analysts’ expectations of $601.14 million. Exact Sciences had a negative […]

AtonRa Partners decreased its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 12.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,530 shares of the medical research company’s stock after selling 1,622 shares during the […]

AtonRa Partners reduced its position in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 12.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,530 shares of the medical research company’s stock after selling 1,622 shares during the quarter. […]

Mayo Clinic increased its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 40.9% in the 1st quarter, Holdings Channel reports. The firm owned 5,151 shares of the medical research company’s stock after purchasing an additional 1,496 shares during the period. Exact Sciences accounts for approximately 0.3% of Mayo Clinic’s holdings, making the stock […]

Operator: Good day and welcome to the Exact Sciences Second Quarter 2023 Earnings Call. Todays call is being recorded. All lines have been placed on mute to prevent any background noise.

/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated...